Disir
Platinum Member
- Sep 30, 2011
- 28,003
- 9,610
- 910
The coronavirus variant discovered in South Africa can "break through" Pfizer/BioNTech's COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is low and the research has not been peer reviewed.
The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease. It matched age and gender, among other characteristics.
The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel's largest healthcare provider, Clalit.
But among patients who had received two doses of the vaccine, the variant's prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.
This sure ain't comforting. So, Pfizer is going to have to work on it.
The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease. It matched age and gender, among other characteristics.
The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel's largest healthcare provider, Clalit.
But among patients who had received two doses of the vaccine, the variant's prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.
South African variant may 'break through' Pfizer vaccine protection, but vaccine highly effective, Israeli study says
The coronavirus variant discovered in South Africa can break through the protection provided by Pfizer Inc and BioNTech's COVID-19 vaccine to some extent, a real-world data study in Israel found. The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across...
news.yahoo.com
This sure ain't comforting. So, Pfizer is going to have to work on it.